Want to see MIST full AI Analyst Report?
MIST Stock Chart & Stats
$1.16
-$0.03(-2.59%)
At close: 4:00 PM EDT
$1.16
-$0.03(-2.59%)
Day’s Range― - ―
52-Week Range$1.00 - $3.06
Previous Close$1.14
Volume1.21M
Average Volume (3M)1.21M
Market Cap
$131.35M
Enterprise Value$157.07
Total Cash (Recent Filing)$170.61M
Total Debt (Recent Filing)$60.07M
Price to Earnings (P/E)―
Beta2.83
Next Earnings
Nov 17, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding124,497,980
10 Day Avg. Volume819,423
30 Day Avg. Volume1,214,359
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)4.06
Price to Sales (P/S)109.60
P/FCF Ratio-3.43
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.50Price Target Upside460.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.84
Revenue Forecast (FY)$3.98M
Bulls Say, Bears Say
Bulls Say
Strong Cash RunwayMilestone's reported ~$184M cash balance explicitly funds the CARDAMYST launch and the ReVeRa‑301 Phase III into H2 2027. This multi-quarter runway materially reduces near-term refinancing pressure, enabling sustained commercial investment and trial execution to prove product economics before new capital is required.
Rapid Commercial LaunchExecuting a national launch within two months and deploying a ~60-rep field force demonstrates operational readiness and commercial competence. Rapid rollout and early prescriber engagement create a durable capability to scale promotional activities as payer coverage grows, supporting sustained adoption over successive quarters.
Major Payer AccessObtaining Express Scripts formulary placement that covers ~25% of commercial lives is a structural advantage: it lowers patient access friction, facilitates prescribing by physicians, and creates a platform for expanding reimbursement. Durable payer support increases the odds of steady refill economics as use grows.
Bears Say
High LeverageDebt of $137.3M against $36.0M equity produces roughly 3.8x leverage, which is elevated for a company without established operating profits. High leverage reduces financial flexibility, raises refinancing risk, and increases the likelihood of dilutive capital raises if commercial ramp or clinical timelines slip.
Sustained Cash BurnPersistent negative operating and free cash flow (~-$51M TTM) and reported quarter burn (~$23.7M) show the business is not yet cash generative. Continued high burn will progressively erode runway absent accelerating revenues or additional financing, constraining strategic choices and increasing dilution risk over the medium term.
Minimal Product RevenueReported Q1 product revenue of $0.2M reflects an extremely early commercial stage with limited refill depth and scale. Low initial sales mean ongoing launch spend must continue to drive adoption; until prescriptions and repeat use broaden, the company remains dependent on external capital despite early traction.
Milestone Pharmaceuticals News
MIST FAQ
What was Milestone Pharmaceuticals’s price range in the past 12 months?
Milestone Pharmaceuticals lowest stock price was $1.00 and its highest was $3.06 in the past 12 months.
What is Milestone Pharmaceuticals’s market cap?
Milestone Pharmaceuticals’s market cap is $131.35M.
When is Milestone Pharmaceuticals’s upcoming earnings report date?
Milestone Pharmaceuticals’s upcoming earnings report date is Nov 17, 2026 which is in 86 days.
How were Milestone Pharmaceuticals’s earnings last quarter?
Milestone Pharmaceuticals released its earnings results on Aug 12, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.195 by -$0.015.
Is Milestone Pharmaceuticals overvalued?
According to Wall Street analysts Milestone Pharmaceuticals’s price is currently Undervalued.
Does Milestone Pharmaceuticals pay dividends?
Milestone Pharmaceuticals does not currently pay dividends.
What is Milestone Pharmaceuticals’s EPS estimate?
Milestone Pharmaceuticals’s EPS estimate is -0.22.
How many shares outstanding does Milestone Pharmaceuticals have?
Milestone Pharmaceuticals has 124,497,980 shares outstanding.
What happened to Milestone Pharmaceuticals’s price movement after its last earnings report?
Milestone Pharmaceuticals reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.195. Following the earnings report the stock price went down -11.417%.
Which hedge fund is a major shareholder of Milestone Pharmaceuticals?
Currently, no hedge funds are holding shares in MIST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Milestone Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.50 (460.34% Upside)
$6.50 (460.34% Upside)
Blogger Sentiment
Neutral
MIST Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 133.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
283.04%
Trailing 12-Months
Company Description
Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.
MIST Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed clear early commercial momentum and important strategic progress: rapid increases in prescribers and prescriptions, a recent and meaningful expansion of commercial formulary coverage to ~50%, initiation of a pivotal Phase III AFib-RVR trial, and a healthy cash position (≈$170.6M) with runway into H2 2027. Offsetting these positives are material near-term financial pressures — minimal product revenue to date, heavy SG&A related to the launch, widening net losses, and dependencies on payer decisions and trial execution (notably patient-reported endpoints and event misclassification risk). Overall the company appears to be in a typical early-launch, high-investment phase with encouraging uptake signals and defined paths to improve revenue as coverage and ASPs normalize, but substantial execution and reimbursement risks remain.View all MIST earnings summariesMIST Stock 12 Month Forecast
Average Price Target
$6.50
▲(460.34% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Seres Therapeutics
―
Avalo Therapeutics
―
Elicio Therapeutics
―
Alto Neuroscience, Inc.
―
Ownership Overview
0.88% Insiders
0.06% Mutual Funds
25.66% Other Institutional Investors
70.69% Public Companies and
Individual Investors